Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (51)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mustacchi, G.
Right arrow Articles by Sasso, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mustacchi, G.
Right arrow Articles by Sasso, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:414-420, 2003
© 2003 European Society for Medical Oncology

Original Paper

Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial

G. Mustacchi1,+, R. Ceccherini1, S. Milani1, A. Pluchinotta2, A. De Matteis3, L. Maiorino4, A. Farris5, A. Scanni6 and F. Sasso On behalf of the Italian Cooperative Group GRETA7,§

1 Oncology Center, University of Trieste; 2 Surgery Unit, General Hospital, Padova; 3 Medical Oncology Unit, National Cancer Institute, Napoli; 4 Medical Oncology Unit, S. Gennaro Hospital, Napoli; 5 Department of Clinical Oncology, University of Sassari; 6 Medical Oncology Unit, Fatebenefratelli and Oftalmico Hospital, Milano; 7 Biostatistics, University of Trieste, Italy

Received 29 July 2002; revised 7 November 2002; accepted 11 December 2002

Background:

To evaluate the efficacy of tamoxifen as primary treatment in women aged over 70 years with operable breast cancer versus surgery followed by adjuvant tamoxifen.

Patients and methods:

Patients randomly received tamoxifen alone (160 mg day 1, then 20 mg/day) for 5 years or surgery followed by tamoxifen (20 mg/day) for 5 years. Overall survival was the main study end point; secondary objectives included breast cancer survival and local control of the disease.

Results:

Between 1987 and 1992, 239 patients were assigned to surgery plus tamoxifen and 235 to tamoxifen alone. Treatment arms were comparable for tumor size, clinical nodal status and performance status. At a median follow-up of 80 months 274 patients had died. No difference between groups had emerged in overall and breast cancer survival. There were 27 local progressions in the surgery plus tamoxifen group and 106 in the tamoxifen-alone group (P = 0.0001). In the surgery plus tamoxifen group, no difference in overall survival had emerged according to the extension of operation.

Conclusions:

The long-term results of the study confirm the 3-year interim analysis already reported. Surgery (radical or minimal) followed by adjuvant tamoxifen does not modify overall and breast cancer survival as compared with tamoxifen alone in early breast cancer of older women. Because of the high rate of local progressions with tamoxifen alone, minimal surgery followed by tamoxifen appears to be the appropriate treatment in such patients. More extensive surgery is not useful. Tamoxifen alone is an adequate alternative treatment in very old or frail patients.

Key words: breast cancer, elderly, tamoxifen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
G. Mustacchi, M. Mansutti, C. Sacco, S. Barni, A. Farris, M. Cazzaniga, M. Cozzi, and C. Dellach
Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study
Ann. Onc., April 1, 2009; 20(4): 655 - 659.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
J. M. Dixon and E. J. Macaskill
Neoadjuvant Endocrine Therapy
ASCO Educational Book, January 1, 2009; 2009(1): 39 - 43.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G Mustacchi, M. Cazzaniga, P Pronzato, A De Matteis, F Di Costanzo, I Floriani, and On behalf of the NORA Study Group
Breast cancer in elderly women: a different reality? Results from the NORA study
Ann. Onc., June 1, 2007; 18(6): 991 - 996.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Crivellari, M. Aapro, R. Leonard, G. von Minckwitz, E. Brain, A. Goldhirsch, A. Veronesi, and H. Muss
Breast Cancer in the Elderly
J. Clin. Oncol., May 10, 2007; 25(14): 1882 - 1890.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. J. Macaskill, L. Renshaw, and J. M. Dixon
Neoadjuvant Use of Hormonal Therapy in Elderly Patients with Early or Locally Advanced Hormone Receptor-Positive Breast Cancer
Oncologist, November 1, 2006; 11(10): 1081 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum
Primary Systemic Therapy of Breast Cancer
Oncologist, June 1, 2006; 11(6): 574 - 589.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Kaufmann, G. N. Hortobagyi, A. Goldhirsch, S. Scholl, A. Makris, P. Valagussa, J.-U. Blohmer, W. Eiermann, R. Jackesz, W. Jonat, et al.
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
J. Clin. Oncol., April 20, 2006; 24(12): 1940 - 1949.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.